Objective
The eukaryotic genome is packaged into chromatin, which needs to be unpacked to provide necessary access by cellular factors for varied cellular functions. However, DNA can be rendered accessible by the action of energy-consuming chromatin remodelling proteins. One such protein is ATRX that harbours an N-terminal plant homeodomain (PHD) and a C-terminal helicase domain that confers ATPase activity and identifies ATRX as a member of the snf2 family member of chromatin remodellers. ATRX has been shown to localize in vivo with constitutive heterochromatin in pericentromeric regions as well as telomeres where it works in complex with DAXX for the deposition of the Histone3.3. Mutations in the ATRX gene give rise to ATR-X syndrome, a severe X-linked mental retardation syndrome often accompanied by alpha-thalassemia. Mounting evidence links ATRX mutations to cancer and to malignancies that depend on a telomerase-independent pathway of telomere maintenance called the ‘alternative lengthening of telomeres (ALT) pathway, linking ATRX to aging. Despite these advances however, there is lack of understanding of the molecular mechanism of ATRX and of its role within these pathologies. The proposed research aims to investigate the structural and functional properties of ATRX, and to define at a molecular level how it interacts with DAXX to remodel chromatin. We will use a combination of biophysical techniques like NMR, Isothermal Calorimetry and western blotting to characterize ATRX interaction with partner proteins. X-ray crystallography, Cryo-electron microscopy and Small angle X-ray scattering techniques will be used to elucidate the structure of ATRX complexes. We will also design assays to measure the enzymatic activity of the ATRX snf2 domain by itself and in presence of DNA and/or its interacting partners. These studies will provide insight into a potential new mechanism of chromatin remodelling and will help us elucidate the consequences of disease-related ATRX mutations.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences health sciences health care sciences
- natural sciences biological sciences genetics mutation
- medical and health sciences basic medicine pathology
- medical and health sciences clinical medicine oncology leukemia
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2014
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
BN1 9RH BRIGHTON
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.